Background Neoadjuvant FOLFIRINOX is a standard-of-care treatment for BRPC patients.
Patients with gBRCAm who have demonstrated improved response to platinum-based …

Background No consensus exists regarding the optimal neoadjuvant treatment paradigm for
patients with borderline resectable pancreatic cancer (BRPC), including the respective roles …

Borderline resectable pancreatic cancer (BRPC) is a potentially resectable disease but is
associated with poorer survival compared to primary resectable disease. There has been no …

Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …

Background Pancreatic cancer often presents as locally advanced (LAPC) or borderline
resectable (BRPC). Neoadjuvant systemic therapy is recommended as initial treatment. It is …

Objective To assess clinical and pathologic efficacy of neoadjuvant FOLFIRINOX for locally
advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Methods Patients …

We conducted an institutional study to compare the clinical and pathological efficacy
between the neoadjuvant therapy (NAT)‐modified FOLFIRINOX (mFOLF) vs nanoparticle …

Background Patients with borderline resectable pancreatic cancer (BRPC) have poor
prognosis with upfront surgery. Methods This was a single-arm Phase 2 trial for clinical and …

Approximately 20% of pancreatic ductal adenocarcinoma (PDAC) patients have (borderline)
resectable pancreatic cancer [(B) RPC] at diagnosis. Upfront resection with adjuvant …

Fluorouracile, oxaliplatin, irinotecan, and leucovorin (FOLFIRINOX) has not been
extensively used in the neoadjuvant setting because of concerns with safety and toxicity. We …